These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 23476074

  • 1. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
    Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC.
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
    [Abstract] [Full Text] [Related]

  • 2. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
    McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
    [Abstract] [Full Text] [Related]

  • 3. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
    Yang SE, Sullivan PS, Zhang J, Govind R, Levin MR, Rao JY, Moatamed NA.
    Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
    [Abstract] [Full Text] [Related]

  • 4. Multicenter clinical experience with the Afirma gene expression classifier.
    Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR.
    J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
    [Abstract] [Full Text] [Related]

  • 5. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH.
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [Abstract] [Full Text] [Related]

  • 6. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
    Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR.
    N Engl J Med; 2012 Aug 23; 367(8):705-15. PubMed ID: 22731672
    [Abstract] [Full Text] [Related]

  • 7. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M, Buratto M, Bruni S, Filieri C, Tagliati F, Trasforini G, Rossi R, Beccati MD, Degli Uberti EC, Zatelli MC.
    J Clin Endocrinol Metab; 2012 Jul 23; 97(7):2354-61. PubMed ID: 22535974
    [Abstract] [Full Text] [Related]

  • 8. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
    Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS.
    J Clin Endocrinol Metab; 2011 Mar 23; 96(3):658-64. PubMed ID: 21239517
    [Abstract] [Full Text] [Related]

  • 9. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov 23; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 10. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell TE.
    Cancer Cytopathol; 2017 May 23; 125(5):313-322. PubMed ID: 28152275
    [Abstract] [Full Text] [Related]

  • 11. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
    Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, Wylie D, Beaudenon-Huibregtse S.
    J Clin Endocrinol Metab; 2015 Jul 23; 100(7):2743-50. PubMed ID: 25965083
    [Abstract] [Full Text] [Related]

  • 12. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method.
    Kim SY, Kim EK, Kwak JY, Moon HJ, Yoon JH.
    Surgery; 2015 Feb 23; 157(2):354-61. PubMed ID: 25616949
    [Abstract] [Full Text] [Related]

  • 13. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
    Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M.
    Clin Endocrinol (Oxf); 2007 May 23; 66(5):678-83. PubMed ID: 17381488
    [Abstract] [Full Text] [Related]

  • 14. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
    Lee SR, Yim H, Han JH, Lee KB, Lee J, Soh EY, Kim DJ, Chung YS, Jeong SY, Sheen SS, Park SH, Kim JH.
    Am J Clin Pathol; 2015 Mar 23; 143(3):437-44. PubMed ID: 25696803
    [Abstract] [Full Text] [Related]

  • 15. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct 23; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 16. Clinical diagnostic gene expression thyroid testing.
    Steward DL, Kloos RT.
    Otolaryngol Clin North Am; 2014 Aug 23; 47(4):573-93. PubMed ID: 25041959
    [Abstract] [Full Text] [Related]

  • 17. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL, Faquin WC, Samir AE.
    AJR Am J Roentgenol; 2015 Oct 23; 205(4):861-5. PubMed ID: 26397337
    [Abstract] [Full Text] [Related]

  • 18. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF, Westra WH, Cooper DS, Ali SZ.
    Cancer Cytopathol; 2017 Sep 23; 125(9):683-691. PubMed ID: 28544601
    [Abstract] [Full Text] [Related]

  • 19. The Combined Use of Fine-Needle Aspiration (FNA) and BRAF V600E Gene Testing: Can it Increase the Definitive Diagnosis Rate of Nodules Categorized as Bethesda III for Papillary Thyroid Carcinoma?
    Lei L, Hong Qing S, Wei L, Ma Mo Yang F, Xiao Xiang Y.
    Am Surg; 2024 Dec 23; 90(12):3209-3215. PubMed ID: 39047144
    [Abstract] [Full Text] [Related]

  • 20. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.
    Acta Cytol; 2011 Dec 23; 55(6):570-5. PubMed ID: 22156468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.